Semax side effects and safety context

The published Semax safety record is unusual in one respect: it is reassuring and thin at the same time. Russian clinical studies covering several hundred patients report few adverse effects and good tolerability, and no signal has emerged in decades of use in that country. But those reports come from short intranasal courses given to supervised patients with cerebrovascular disease, and the adverse-event data are summarised rather than itemised. There is no equivalent of an FDA-style adverse reactions table with frequencies, because no regulator outside Russia has ever compiled one.

The 187-patient study of chronic cerebrovascular insufficiency explicitly addressed tolerability, reporting a low incidence of adverse effects and good tolerance across patient groups including elderly patients (Gusev, Skvortsova and Chukanova 2005). The 110-patient post-stroke rehabilitation study reported outcomes and BDNF levels without describing dose-limiting toxicity, using a regimen of 6,000 mcg/day intranasally for 10 days, repeated after a 20-day interval (Gusev et al. 2018).

That is the whole of the structured human safety literature in English-indexed journals. Reported effects elsewhere in the literature and in user accounts are mild and nonspecific: local nasal irritation from the intranasal solution, headache, and changes in alertness or sleep. None of these have been quantified against a placebo arm, which means none of them can be separated from background symptom noise.

"Well tolerated" is always a claim about a specific exposure in a specific population. In the Semax case, that exposure has four features that most present-day use does not share:

• Short courses. Ten to fourteen days, sometimes repeated after a gap — not continuous use for months.
• Intranasal delivery of a pharmacy-prepared solution of known concentration.
• Patients under medical supervision, being monitored for a neurological condition anyway.
• No healthy-volunteer safety programme of the kind a Western approval would require.

Each departure from those conditions moves a user outside the population in which the tolerability claim was generated. Repeated long-term use in healthy adults is the most common departure and the least studied one.

Semax's pharmacology suggests where to look, even where data are absent. It binds specifically in rat basal forebrain with nanomolar affinity and raises BDNF there within hours of intranasal dosing (Dolotov et al. 2006). A compound that measurably changes neurotrophic signalling in a specific brain region is not pharmacologically inert, and the open question is what sustained upregulation does over months or years — a question no study has addressed in either direction.

Two further practical points follow from the pharmacokinetics. Semax crosses into the brain quickly after intranasal dosing and is degraded quickly, with the tripeptide Pro-Gly-Pro as its main metabolite (Shevchenko et al., Bioorg Khim 2006). Rapid clearance limits accumulation, which is reassuring; it also means effects are short-lived, which is part of why the studied regimens involve repeated daily dosing. Interactions with medications acting on the nervous system have not been formally mapped.

With any unapproved peptide, a large share of real-world risk comes from the vial rather than the pharmacology. Identity, purity, sterility, endotoxin content, and label accuracy are unverified for research-grade material, and none of the Russian clinical data apply to a product the buyer cannot confirm is Semax. Injectable preparations sold internationally differ from the intranasal formulation every published study used, so even the modest safety reassurance available does not carry across. Broader context on this category of risk is in what are the risks of peptides.